CNS Clinical Trials: World Market Prospects 2011-202629 Sep 2011 • by Natalie Aster
Analysis of the CNS clinical trials sector is limited by the availability of quantitative data on global clinical development operations and other activity. The past few years have seen increased registration of clinical trials on the FDA website, owing to new mandates from FDA, listed in the FDA Modernization Act of 1997. Although, these numbers do not represent the global clinical trial activity, it still is considered to be a substantial subset of the entire market scenario.
For the purposes of the report “CNS Clinical Trials: World Market Prospects 2011-2026” by Visiongain, the CNS clinical trials market is defined as the costs incurred by trial sponsors in conducting phase I-IV clinical trials for CNS disorders. That includes both government and industry sponsored trials. The CRO market is defined as the revenue achieved by CROs through services provided in CNS clinical trials. As well as trial management, costs incurred include patient recruitment and assessment, training and data management. Pre-clinical costs are not included in the total market, although factors relating to pre-clinical stages are discussed for the impact they have on later, clinical stages.
Published: December 2010
Price: US$ 2,350.00
Report Sample Abstract
Expertise in CNS Clinical Trials
Quintiles reports that it has over 25 years of experience in conducting CNS clinical trials. The company says that it was involved in the development or commercialisation of all the top 20 best selling CNS products in 2008.
Quintiles has experience in clinical trial support for a number of CNS diseases, including Alzheimer’s, multiple sclerosis, Parkinson’s, epilepsy, depression, stroke and schizophrenia.
In line with the rest of the CNS clinical trial industry, Quintiles has been gaining experience and expertise in the use of biomarkers and neuroimaging for establishing endpoints for trials. The company says that it is a pioneer in the use of Transcranial Magnetic Stimulation (TMS) for phase I clinical trials. It also uses PET and MRI for imaging in its phase I-III trials.
Recent Developments and Growth Strategies
In 2010, Quintiles announced the expansion of its existing research facility in London, and opening of a new phase I unit in Hyderabad, India. The expansion of the company’s drug research unit at Guy’s Hospital in London will reportedly increase its capacity to perform proof-of-concept trials. Additionally, the expansion extends Quintiles’ collaboration with King’s College London and Guy’s and St Thomas’ NHS Foundation Trust.
The Indian unit was created in partnership with Apollo Hospitals Group, and will be Quintiles' first phase I unit in India when it opens in 2010. The company’s other phase I facilities are in Kansas, Lulea and Uppsala. At present, Quintiles reportedly has a phase I capacity, which will further increase in late 2010 with opening of the facility in India. Through this expansion, the company is better equipped to manage the increase in outsourcing of phase I trials. Effective early-stage research can help control the cost and increase the speed of drug development.
Covance was established in 1997 as independent public company. Through acquisitions of other small CROs globally, the company has expanded and, in 2009, was the world’s second largest CRO. It specialises particularly in oncology and biologics, with services spanning pre-clinical and clinical development and approval processes.
More information can be found in the report “CNS Clinical Trials: World Market Prospects 2011-2026” by Visiongain.
To order the report or ask for sample pages contact firstname.lastname@example.org
Tel: +44 208 144 6009
Fax: +44 207 900 3970